I have been engaged in the research of molecular stratification diagnosis and accurate treatment of hematological tumors for a long time. I have made innovative achievements in the recurrence of hematological tumors, the treatment of drug resistance and its mechanism, and the optimization of clinical treatment. The 5-year survival rate of the treated patients can reach the international leading level. A series of explorations have been carried out in the field of individualized treatment and prognosis of hematological tumors. The results are cited by the American NCCN guidelines and are widely used all over the world. Presided over the research of National Nature Fund, Guangdong Nature Fund, Guangdong Science and Technology Program, Guangdong Department of Health, etc., selected into the Young teacher training Program of Sun Yat-sen University, participated in writing 4 academic monographs, and published more than 30 related academic papers in international mainstream authoritative magazines such as BJC,  JHO, Oncotarget, BMC Cancer, etc.

Acute leukemia, multiple myeloma, extranodal NK/T cell lymphoma

Graduated from the first affiliated Hospital of Guangzhou Medical College with a master’s degree in 2009, and in 2012, graduated from Sun Yat-sen University Cancer Center with doctorate.

1. Hua Wang, Liang Wang, Pei-dong Chi,et al.High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. British Journal of Cancer (2016) 114, 463–468;

2. Wang H(#), Hu WM(#), Xia ZJ, Liang Y, Lu Y, Lin SX(*), Tang H(*), High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens. Journal of Cancer. 2019; 10(14): 32

3. Hua Wang, Liang Wang, Yue Lu,et al.Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients. OncoTargets and Therapy 2016:9 587–595 39-3245;

4. Xi-wen Bi(#), Hua Wang(#), Wen-wen Zhang(#), Jing-hua Wang, Wen-jian Liu, Zhong-jun Xia, Hui-qiang Huang, Wen-qi Jiang, Yu-jing Zhang, Liang Wang(*).PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. Journal of Hematology & Oncology (2016) 9:109 );

5. Pengfei Li(#), Li Jiang(#), Xinke Zhang, Jun Liu, Hua Wang(*).CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. BMC Cancer 2014, 14:890.

6. Hua Wang, Pengfei Li, Liang Wang,et al.High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type. Ann Hematol.2015 Sep;94(9):1535-44.

7. Hua Wang, Zhi-Jun Wuxiao, Jiayu Zhu,et al.Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leukemia & Lymphoma 2015; 56(4): 971–977 .

8. Hua Wang, Jia-yu Zhu, Cheng-cheng Liu,et al. Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma. Med Oncol (2015)32:370.

9. Hua Wang, Liang Wang, Zhijun Wuxiao,et al.Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy. Onco Targets Ther. 2015 Sep 14;8:2589-99.

10. Hua Wang, Pengfei Li, XinKe Zhang,et al.Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Oncology Letters 2016;12: 825-836.

11. Liang Wang(#)(*),  Hua Wang(#), Peng-fei Li, Yue Lu, Zhong-jun Xia,  Hui-qiang Huang , Yu-jing Zhang.CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. Ann Hematol 2015 Aug;94(8):1381-8.

12. Li C, Wuxiao ZJ, Chen X, Hua Wang*(通讯作者) et al. A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience. Cancer Res Treat. 2020;52(2):573–585. doi:10.4143/crt.2019.542

13. Liu WJ(#) ,Wang H(#), Peng XW, Wang WD, Liu NW, Wang Y, Lu Y(*).Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro. Onco Targets Ther.2018 Oct 8;11:6605-6615

14. Hua Wang, Qi-Rong Geng, Liang Wang , Yue Lu. Curcumin potentiates antitumor activity of L -asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia. Leukemia & Lymphoma, Month 2012; Early Online, 1–7

15. Chun Li(#),Xiuyu Cai(#), Xiaoqin Chen1, Yang Liang1, Zhongjun Xia(*), Hua Wang(*)Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. Int J Hematol DOI: 10.1007/s12185-019-02703-0)2019

16. Hua Wang • Xiao-Qin Chen • Qi-Rong Geng •Pan-Pan Liu • Gui-Nan Lin • Zhong-Jun Xia •Yue Lu. Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia. Int J Hematol (2011) 94:163–168

17. Wen-jian Liu(#), Hua Wang(#), Wei-da Wang, Meng-yuan Zhu, Cheng-cheng Liu,Jing-hua Wang, Yue Lu(*).Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coliasparaginase: a retrospective single-center study. Sci Rep. 2016 Dec 21;6:39463

18. Cheng-cheng Liu(#), Hua Wang(#), Wei-da Wang (#),Liang Wang, Wen-jian Liu, Jing-hua Wang ,Qi-rong Geng Yue Lu(*).ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia. Cell Physiol Biochem 2018;46:1525-1535

19. Jiayu Zhu, Hua Wang*(通讯作者), Cheng Cheng Li,et al.The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer Res Clin Oncol. 2016 Nov;142(11):2339-45.

20. Zhu JY, Liu CC, Wang L, Zhong M, Tang HL, Wang H*(通讯作者). Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study. Journal of Cancer.2017;8:737-743.

Updated May 2020 by International Office, Sun Yat-sen University Cancer Center